Lifecore Biomedical's Total Assets for the quarter that ended in Feb. 2025 was $237.7 Mil.
During the past 12 months, Lifecore Biomedical's average Total Assets Growth Rate was -4.50% per year.
During the past 3 years, the average Total Assets Growth Rate was -21.20% per year.
During the past 5 years, the average Total Assets Growth Rate was -17.80% per year.
During the past 10 years, the average Total Assets Growth Rate was -1.80% per year.
During the past 13 years, Lifecore Biomedical's highest 3-Year average Total Assets Growth Rate was 49.70%. The lowest was -24.30%. And the median was 7.10%.
The historical data trend for Lifecore Biomedical's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Lifecore Biomedical's Total Assets for the fiscal year that ended in May. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (NAS:LFCR) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Feb. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Lifecore Biomedical's Asset Turnover for the quarter that ended in Feb. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Lifecore Biomedical Total Assets Related Terms
Thank you for viewing the detailed overview of Lifecore Biomedical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LFCR has been successfully added to your 